Next Article in Journal
The Trends of Complicated Acute Colonic Diverticulitis—A Systematic Review of the National Administrative Databases
Previous Article in Journal
The Effect of Mean Platelet Volume/Platelet Count Ratio on Dipper and Non-Dipper Blood Pressure Status
Open AccessArticle

Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy

1
Division of Medicine, Department of Pulmonary Diseases, Turku University Hospital, 20521 Turku, Finland
2
Department of Pulmonary Diseases and Clinical Allergology, University of Turku, 20521 Turku, Finland
3
Auria Biobank, University of Turku, and Turku University Hospital, 20521 Turku, Finland
4
Tampere University Hospital, 33521 Tampere, Finland
5
Boehringer Ingelheim Finland Ky, 00180 Helsinki, Finland
*
Author to whom correspondence should be addressed.
Medicina 2019, 55(11), 743; https://doi.org/10.3390/medicina55110743
Received: 3 September 2019 / Revised: 26 October 2019 / Accepted: 12 November 2019 / Published: 16 November 2019
Background and Objectives: Evaluation of data from electronic health care records could help in guiding towards more rational drug treatments. This single center study evaluated clinical characteristics that could be associated with disease progression. Methods: This was a real world data (RWD) study using existing data from the registries of a university hospital. Patients had lung adenocarcinoma and they had received 1st line treatment. Treatment patterns and survival parameters were characterized and clinical characteristics of the patients were evaluated together with their association with disease progression. Results: 80 stage III/IV patients fulfilling inclusion criteria were identified. Mean age was 62 years and 61% were men. In total, 65% were current smokers and 82% had performance status (ECOG) 0/1. Median progression free survival (mPFS) and median overall survival (mOS) for stage III and IV patients were 8.5 and 5.4 months, and 21.9 and 8.6 months, respectively. The study found that 69% of patients progressed within 9 months from the start of the 1st line treatment. Poor performance status (ECOG 3), male gender, and smoking suggested faster disease progression. Most had received cis/carboplatin-based treatment in the 1st line. Cisplatin regimens were associated with more complete responses and better PFS and OS than the carboplatin ones. Conclusions: By combining algorithmic and manual validation of electronic health care records, clinically valid characteristics and outcomes could be evaluated and presented. This approach forms a basis for tools such as quality registries that can guide treatment decisions. View Full-Text
Keywords: non-small cell lung cancer; adenocarcinoma; chemotherapy; real world data non-small cell lung cancer; adenocarcinoma; chemotherapy; real world data
Show Figures

Figure 1

MDPI and ACS Style

Vilhonen, H.; Kurki, S.; Laitinen, T.; Hirsjärvi, S. Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy. Medicina 2019, 55, 743.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop